Interleukin-21: a new mediator of inflammation in systemic lupus erythematosus

J Biomed Biotechnol. 2010:2010:294582. doi: 10.1155/2010/294582. Epub 2010 Jun 28.

Abstract

Systemic Lupus Erythematosus (SLE) is an autoimmune disorder characterized by excessive production of a variety of autoantibodies and a wide range of clinical manifestations. Pathogenesis of SLE is complex and not fully understood. There is however evidence that B and T cells are critical to the development of disease, and that T cell-derived cytokines are involved in the SLE-associated inflammatory response. One such cytokine seems to be interleukin (IL)-21, the latest identified member of the gamma-chain-related cytokine family. IL-21 has an important role in the control of the growth, survival, differentiation, and function of both T and B cells, and excessive production of IL-21 has been associated with the development of multiple immune-mediated diseases. Here we review data supporting the involvement of IL-21 in the pathogenesis of SLE.

Publication types

  • Review

MeSH terms

  • Animals
  • B-Lymphocytes / metabolism
  • Disease Models, Animal
  • Humans
  • Inflammation Mediators / metabolism*
  • Interleukin-21
  • Interleukins / metabolism*
  • Lupus Erythematosus, Systemic* / immunology
  • Lupus Erythematosus, Systemic* / metabolism
  • Mice
  • T-Lymphocytes / metabolism

Substances

  • Inflammation Mediators
  • Interleukins
  • Interleukin-21